The Potential Effect of Ending Centers for Disease Control and Prevention Funding for HIV Tests: A Modeling Study in 18 States
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciag038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Ruchita Balasubramanian und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Centers for Disease Control and Prevention, U.S., HIV Infections, HIV Testing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMHD NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Timely HIV diagnosis and treatment is critical to preventing transmission. The US Centers for Disease Control and Prevention (CDC) provides funding for HIV testing to local health departments and community organizations. We sought to estimate the number of additional HIV infections that would result from ending or interrupting CDC funding for HIV tests in US states.
Methods
We used a validated model of HIV transmission to simulate HIV epidemics in 18 US states. We projected incidence forward under 3 scenarios where all CDC-funded HIV testing ends in October 2025 and (1) never resumes, (2) returns to previous levels between January and December 2027, and (3) returns from January to December 2029. We calculated the excess incident HIV infections compared to a scenario where CDC-funded testing continues uninterrupted.
Results
If CDC funding for HIV tests were to end on 1 October 2025, we project 12 719 additional HIV infections across 18 states by 2030 (95% credible interval, 4547–21 896)—an increase of 10%. The projected effects varied by state, ranging from a 2.7% increase in Washington (1.0%–4.7%) to a 29.9 increase in Louisiana (9.4%–59.9%). States that perform more CDC-funded tests and states with more rural HIV epidemics were projected to see greater rises in incidence.
Conclusions
Disruptions to CDC-funded HIV testing would substantially increase new infections, particularly in states with more rural epidemics. These findings demonstrate the value of the CDC's HIV testing activities in curbing the spread of HIV in the United States.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
- Department of Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- Tulane School of Social Work, New Orleans, Louisiana, USA.
ORCID-Profile: Ruchita Balasubramanian, William P Hanage, D Scott Batey, Keri N Althoff, Parastu Kasaie
Förderung
- NIMHD NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Balasubramanian, R., Schnure, M., Forster, R., Hanage, W. P., Batey, D. S., Althoff, K. N., Gebo, K. A., Dowdy, D. W., Shah, M., Kasaie, P., & Fojo, A. T. (2026). The Potential Effect of Ending Centers for Disease Control and Prevention Funding for HIV Tests: A Modeling Study in 18 States. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag038
Vancouver
Balasubramanian R, Schnure M, Forster R, Hanage WP, Batey DS, Althoff KN, et al. The Potential Effect of Ending Centers for Disease Control and Prevention Funding for HIV Tests: A Modeling Study in 18 States. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag038
BibTeX
@article{Balasubramanian2026,
author = {Balasubramanian, Ruchita and Schnure, Melissa and Forster, Ryan and Hanage, William P and Batey, D Scott and Althoff, Keri N and Gebo, Kelly A and Dowdy, David W and Shah, Maunank and Kasaie, Parastu and Fojo, Anthony T},
title = {The Potential Effect of Ending Centers for Disease Control and Prevention Funding for HIV Tests: A Modeling Study in 18 States},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag038}
}
EUVIMED